Abstract
The members of Rho/ROCK signaling pathway are well-established regulators of actin cytoskeleton and dynamics. Accumulating evidence demonstrates their key roles in other biological processes including polarity, motility, invasion, cell cycle progression, and survival. Aberrant Rho/ROCK signaling have been implicated in both preclinical and clinical samples of several cancers. Mutations of Rho GTPases and ROCK isoforms (ROCK1 and ROCK2) have been reported in tumor samples. In addition, their elevated expression levels have been associated with poor outcome in those tumors. Therefore, Rho/ROCK family genes serve as promising candidates for therapeutic targeting in several cancers. This review focuses on the recent progress in therapeutic targeting of the Rho/ROCK signaling pathway in cancer. In particular, we focus on the potential utility of inhibitors of ROCK, downstream effectors of Rho GTPases, as they have been considered more specific to inhibit Rho/ROCK activity. Although no effective drugs targeting Rho/ROCK activity are available for the clinical management of cancer, studies using drugs that pharmacologically inhibit ROCK isoforms suggest a promising future. AT13148, an inhibitor of members of AGC kinase family including ROCK1 and ROCK2, is in phase 1 clinical trial initiated in 2012 for the treatment of advanced solid tumors (ClinicalTrials.gov identifier NCT01585701). A deeper understanding of this pathway using isoform-specific inhibitors of Rho kinases (ROCK1 and ROCK2) may add new treatment options for future precision cancer therapy improving the clinical utility of this pathway.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Porter AP, Papaioannou A, Malliri A. Deregulation of Rho GTPases in cancer. Small GTPases. 2016;7(3):123–38.
Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846.
Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4(5):387–98.
Wei L, et al. Novel insights into the roles of Rho kinase in cancer. Arch Immunol Ther Exp. 2016;64(4):259–78.
Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem. 2013;61(3):185–98.
Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629–35.
Kale VP, et al. The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migration. Cancer Lett. 2015;361(2):185–96.
Amin E, et al. Rho-kinase: regulation, (dys)function, and inhibition. Biol Chem. 2013;394(11):1399–410.
Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20(2):242–8.
Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci. 2010;67(2):171–7.
Ying H, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 2006;5(9):2158–64.
Nakajima M, et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol. 2003;459(2–3):113–20.
Teiti I, et al. In vivo effects in melanoma of ROCK inhibition-induced FasL overexpression. Front Oncol. 2015;5:156.
Patel RA, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012;72(19):5025–34.
Fagan-Solis KD, et al. The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem. 2013;114(6):1385–94.
Tsai CC, et al. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. Biochem Pharmacol. 2011;81(7):856–65.
Patel RA, et al. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene. 2014;33(5):550–5.
Vigil D, et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012;72(20):5338–47.
Xi Y, et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2016;478(1):330–6.
Sadok A, et al. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res. 2015;75(11):2272–84.
Conflict of Interest
The author has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gökmen-Polar, Y. (2019). Roles of Rho/ROCK in Cancer Signaling. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)